Medications

This slide set outlines the results of the post-trial monitoring of UKPDS which examined whether risk reductions for microvascular and macrovascular disease, achieved with the use of improved blood-pressure control during the trial, were sustained.

A collection of downloadable PowerPoint slides summarizing the primary and follow-up UKPDS findings. The aim of the UKPDS was to determine the effect of intensive glycemic control on the incidence of complications in patients with type 2 diabetes.

The UKPDS has so far generated an astonishing 93 original research papers. medwireNews​​​​​​​ rounds them up.

Twenty years after the publication of the primary findings, medwireNews talks to longtime UKPDS investigator Professor David Matthews (University of Oxford, UK) about the struggles of the team to bring the trial to completion and the impact of the findings on diabetes care.

Editorial Board member Jay Shubrook succinctly delivers his strategies for initiating insulin therapy for the first time in patients with type 2 diabetes.

Advisory Board member Clipper Young recounts an experience of starting a patient with erectile dysfunction on the path to appropriate treatment for him and his diabetes.

Editorial Board member and Endocrinologist, Sanjay Kalra comments on the issues raised by a clinical case involving sodium glucose cotransporter 2 inhibitor therapy alongside a restrictive diet.

A patient discusses their experience of living with type 2 diabetes, including their experience of diagnosis and self-management, education and adoption of SGLT2 inhibitors to treat the disease.

Advisory Board member Theresa Smyth tackles an emergency case in a type 2 diabetes patient treated with empagliflozin. What went wrong and how should he be managed?

Editorial Board member Lori Berard discusses how to meet and overcome the challenges that follow the initial insulin prescription in patients with type 2 diabetes (11:53).

Carmen Soto and David Strain provide their insights on clinical inertia in diabetes care and present the co-production model of open communication as an innovative means to address this widespread clinical issue.

Editorial Board member Lori Berard talks through the stages and challenges associated with preparing type 2 diabetes patients for insulin therapy (9:00).

Sanjay Kalra and Silver Bahendeka, East Africa Diabetes Study Group Chair, provide an overview of the latest insulin guidance developed to aid management in a challenging region, facing familiar struggles.

Editorial Board member Sanjay Kalra presents his view on the march toward greater integration of digital health technologies and how traditional approaches to diabetes management are already changing.

Can you diagnose the atypical form of diabetes presented in our fourth patient case study? Test your knowledge with Editorial Board member, Jay Shubrook.

Diabetes and endocrinology Consultant and Advisory Board member Terence Pang highlights the benefits that a structured approach to glycemic goal setting can bring to your practice and patients with type 1 diabetes.

medwireNews provides a brief overview of the published and ongoing dipeptidyl peptidase-4 inhibitor cardiovascular outcomes trials.

As the utility and availability of devices surges, so too do patient expectations. Advisory Board member Katharine Barnard provides key consultation questions to help determine your patients’ greatest needs and obstacles.

With the 2017 NaDIA results showing some positive trends in inpatient diabetes care, medwireNews talks to national clinical lead Gerry Rayman about the tools and tactics to deliver the best patient outcomes.

Experts review the evidence and best clinical practices of initiating and titrating insulin in patients with type 2 diabetes and provide guidance and practical recommendations for the healthcare community.